Physician profile
Michael D Harder
NPI 1427064146
$2,140.69
in general payments reported to CMS, 2019-2025
29 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $39.50 · 2022: $201 · 2023: $497 · 2024: $610 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488 · Education: $57.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,488.15 |
| Education | $57.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $472.63 | 2022-2025 | |
| Pfizer INC. | $268.08 | 2019-2025 | |
| Amgen INC. | $221.33 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $188.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $130.25 | 2019-2025 | Breztri, Farxiga |
| Nestle Healthcare Nutrition INC. | $100.77 | 2023 | |
| Aimmune Therapeutics, INC. | $95.94 | 2024 | |
| Vanda Pharmaceuticals INC. | $74.57 | 2024-2025 | Fanapt, Hetlioz |
| Astellas Pharma US INC | $58.22 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $51.29 | 2019-2025 | Bexsero, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $46.71 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $44.14 | 2024-2025 | Camzyos |
| Otsuka America Pharmaceutical, INC. | $38.67 | 2022-2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $36.60 | 2025 | Keveyis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.14 | 2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.05 | 2022-2025 | Jardiance |
| Shire North American Group INC | $30.16 | 2019 | |
| Pacira Therapeutics, INC. | $27.19 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.12 | 2019-2022 | |
| Allergan, INC. | $26.48 | 2019 | |
| Alkermes, INC. | $21.62 | 2025 | Aristada, Lybalvi |
| Sanofi Pasteur INC. | $17.92 | 2019 | |
| Corium, LLC | $17.06 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $15.60 | 2024 | Gardasil, Vaxelis, Gardasil 9 |
| Abbott Laboratories | $15.22 | 2023 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $14.44 | 2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $13.96 | 2023 | Quviviq |
| Radius Health, INC. | $13.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.